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Uveitis is less common in children than in adults, and its diagnosis and management 
can be particularly challenging. Young children are often asymptomatic either 
because of inability to express complaints or because of the truly asymptomatic 
nature of their disease. Even in advanced cases, parents may not be aware of severe 
visual impairment until the development of externally visible changes such as band 
keratopathy, strabismus, or leukocoria. Therefore, the diagnosis is often delayed and 
severe complications may be seen at the time of initial visit. Young children may not 
be cooperative for a complete ocular examination and subtle findings of intraocular 
inflammation such as trace cells may be easily missed in the early stages of the disease. 
Children, in general, tend to have more severe and chronic intraocular inflammation 
that frequently results in ocular complications and visual loss. In children who present 
with amblyopia or strabismus, a careful examination is required to rule out uveitis as 
an underlying cause. Delayed and variable presentations cause a distinct challenge in 
the diagnosis of uveitis in children, furthermore differential diagnosis also requires 
awareness of etiologies which are different from adults. There are unique forms of 
uveitis and masquerade syndromes in this age group, while some entities commonly 
encountered in adults are rare in children.
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EPIDEMIOLOGY
In a population-based study in Finland, the 
yearly incidence of uveitis was found to be 4.3 
per 100,000 in children and 27.2 per 100,000 in 
adults; prevalence rates were 27.9 and 93.1 per 
100,000 respectively.1 In a study conducted in 
district hospitals in the UK, the incidence of 
pediatric uveitis increased with age from 3.15 
per 100,000 children aged 0 to 5 years, to 6.06 
per 100,000 of those between 11 and 15 years of 
age.2 Pediatric cases account for less than 10% 
of all cases of uveitis in large series reported 
from referral centers.
As in adults, there are variations in the 
geographic and ethnic distribution of various 
infectious and noninfectious uveitic entities in 
children. Table 1 shows the types of involvement 
and the most common diagnoses in pediatric 
uveitis series reported from various countries.1-18 
Anterior uveitis is the most common form of 
involvement in almost all series. Up to 60% 
of patients have idiopathic uveitis. Juvenile 
idiopathic arthritis (JIA) associated anterior 
uveitis is the leading cause in series reported 
from Northern European countries and from the 
USA, whereas it is less frequent in Mediterranean 
and Middle Eastern countries as well as in India. Pediatric Uveitis; Tugal-Tutkun
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In contrast, while Behçet’s disease accounts for 
11% of pediatric uveitis in Turkey and 5-6% in 
Israel and Tunisia, it is very rare in European 
countries, the USA and India. Vogt-Koyanagi-
Harada disease is distinctly more common in 
Saudi Arabia. Pars planitis has been reported 
as a distinct entity in some series, but was 
included among unspecified idiopathic cases 
in others. Therefore, it is difficult to compare 
the frequency of idiopathic pars planitis among 
published series. Among infectious causes of 
uveitis in children, toxoplasmosis is the most 
common etiology. Herpetic anterior uveitis 
is uncommon in childhood irrespective of 
geographic region. Tuberculosis has been 
reported in 3.9% of pediatric uveitis cases in 
India, where the disease is endemic.14
DIAGNOSTIC ENTITIES
JIA-associated Anterior Uveitis
JIA is the most common systemic association 
of pediatric uveitis. It is defined as arthritis of 
at least 6 weeks’ duration without any other 
identifiable cause in children younger than 
16 years of age. The International League of 
Associations for Rheumatology (ILAR) has 
Authors/
country
Year/ N
Anterior
uveitis
Intermediate
uveitis
Posterior
uveitis
Panuveitis Idiopathic JIA Toxoplasmosis
Behçet’s 
disease
VKH
Herpetic 
uveitis
Tugal-Tutkun et 
al /USA [3]
1996/130 58.4% 20% 13.8% 7.6% 36.8% 41.5% 7.7% 0.7% 1.5% 2.2%
Pivetti-Pezzi/
Italy [4]
1996/267 33.3% 25.1% 26.6% 15% 54.3% 9.4% 11.6% 2.2% 1.5% 5.6%
Soylu et al /
Turkey [5]
1997/90 33.3% 8.9% 23.3% 34.4% 34.4% 3.3% 25.6% 11.1% - 5.1%
Paivönsalo-
Hietanen et al/ 
Finland [1]
2000/55 90.9% 1.8% 5.5% 1.8% 47.3% 36.3% 5.5% - - 5.5%
Stoffel et al/ 
Switzerland [6]
2000/70 57% - 14% 29% 54% 34.3% NA 1.4% - NA
De Boer et al /
Netherlands [7]
2003/123 36% 24% 19% 21% 53.7% 20% 10% - - 3.3%
Kadayifcilar et 
al/ Turkey [8]
2003/219 43.4% 11.9% 31% 13.7% 36% 13.2% 21% 10.9% 0.5% 0.9%
Edelsten et al/
UK [2]
2003/249 70% - 30% - 44% 47% 2% - - -
Azar et al/
Australia [9]
2004/40 66% 5.7% 13.2% 15.1% 60% 17.5% 2.5% - - 12.5%
Rosenberg et al/ 
USA [10]
2004/148 30.4% 27.7% 23.7% 18.2% 26.4% 23% 7.4% 0.7% 0.7% 2%
Kump et al/
USA [11]
2004/269 56.9% 20.8% 6.3% 16% 51.7% 33% 3.4% 0.3% 0.7% 1.5%
Ben Ezra et al/
Israel [12]
2005/276 13.4% 41.7% 14.1% 30.8% 25.4% 14.9% 7.2% 4.7% 1.1% 3.6%
Khairallah et al/ 
Tunisia [13]
2006/64 31.3% 31.3% 20.3% 17.2% 49.9% 6.2% 14.1% 6.2% 1.5% 6.2%
Rathinam et al/
India [14]
2007/616 59.9% 8.4% 11% 20.6% 32.5% 1.8% 4.7% - 0.6% 1.8%
Kazokoglu et al/ 
Turkey  [15]
2008/48 NA NA NA NA 58.3% 12.5% 12.5% 10.4% - -
Smith et al/
USA[16]
2009/527 44.6% 28% 14.4% 12.9% 29% 21% 5% 2% 3% NA
Paroli et al/
Italy [17]
2009/257 47.8% 19.4% 24.9% 7.8% 12.8% 19.9% 15.1% 2.9% 1.5% 5.8%
Hamade et al/
Saudi Arabia [18]
2009/163 42% 20% 7% 31% 50% 15% 4% 5% 16% 2%
Table 1. Pediatric uveitis series reported from various countries
JIA: Juvenile idiopathic arthritis; VKH: Vogt-Koyanagi-Harada disease; NA: not availablePediatric Uveitis; Tugal-Tutkun
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classified JIA into seven subtypes. Patients 
with systemic-onset JIA have extraocular 
manifestations such as fever, rash, hepato-
splenomegaly, lymphadenopathy, and serositis. 
Uveitis is extremely rare in this subtype. The 
oligoarticular subtype is diagnosed when fewer 
than 5 joints are involved during the first 6 
months of the disease. Chronic anterior uveitis 
is most commonly associated with oligoarticular 
JIA. This subtype is defined as extended 
oligoarthritis when more joints become involved 
after 6 months. Polyarticular JIA is diagnosed 
when 5 or more joints are affected during the 
first 6 months of the disease. Polyarticular 
JIA may be rheumatoid factor (RF) positive 
or negative. Uveitis is rare in the RF-positive 
group, however approximately 10% of patients 
with RF-negative polyarticular JIA develop 
uveitis. Psoriatic arthritis is a less common 
subtype of JIA which may be associated with 
chronic anterior uveitis in 10-20% of cases. 
Enthesitis-related arthritis typically occurs in 
older boys who are often HLA-B27 positive. 
Acute unilateral anterior uveitis is the typical 
form of ocular involvement in these patients. 
Patients with arthritis who do not fulfill any 
of these categories are classified as the “other” 
JIA subgroup.19, 20
Risk factors for ocular involvement 
in patients with JIA include female sex, 
oligoarticular arthritis, young age at onset 
of arthritis, antinuclear antibody (ANA) 
seropositivity and RF seronegativity. 21
Children with chronic anterior uveitis 
associated with JIA are typically asymptomatic 
and therefore routine ophthalmologic screening 
is essential for early diagnosis and timely 
treatment. Otherwise, affected subjects may 
present after development of serious ocular 
complications and severe visual impairment. 
Ocular condition at the first visit is the most 
significant predictor of visual outcome. Onset 
of uveitis before or early after the onset of 
arthritis has also been reported as a predictor 
of poor visual outcome. Screening guidelines 
have been developed22; patients with oligo- or 
polyarticular JIA with onset of arthritis at 6 
years of age or younger, duration of arthritis 
4 years or less, and ANA-seropositivity should 
be screened at 3-month intervals.
JIA-associated anterior uveitis is typically 
bilateral, nongranulomatous, and has a chronic 
relapsing course. However, a granulomatous 
disease does not exclude the diagnosis (Fig. 1). 
Mutton-fat keratic precipitates (KPs) or iris 
nodules, reminiscent of sarcoidosis, have been 
reported in 24% of white and 56% of non-white 
patients.23 The most common complications of 
JIA-associated anterior uveitis include band 
keratopathy (Fig. 2), cataract, posterior synechiae 
(Fig. 3), glaucoma, maculopathy, hypotony and 
amblyopia.24,25 In a recent study, 84% of eyes 
with JIA uveitis were found to have maculopathy 
on optical coherence tomography.26 The presence 
of complications at the time of initial visit and 
high anterior chamber flare values by laser flare 
photometry are risk factors for development 
Figure 1. Slit lamp photograph shows medium-sized 
granulomatous keratic precipitates located inferiorly in 
a child with JIA-associated anterior uveitis.
Figure 2. Diffuse illumination at the slit lamp shows 
severe band keratopathy in the left eye of a boy with JIA-
associated anterior uveitis.Pediatric Uveitis; Tugal-Tutkun
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of new complications and poor visual 
prognosis.25,27,28 Early development of cataract 
requiring surgery has been associated with the 
presence of posterior synechiae at the time of 
diagnosis.29 Early immunomodulatory treatment 
reduces the risk of ocular complications and 
visual loss.24,25,29 Since high anterior chamber 
flare is associated with an increased risk of 
visual loss independent of anterior chamber 
cells,28 children with high flare should be 
treated aggressively with the aim of reducing 
flare to the minimum possible level.
Chronic anterior uveitis can also occur in 
children without systemic disease associations. 
In a cohort of 115 patients with chronic anterior 
uveitis, no significant association was found 
between the presence of systemic disease (JIA) 
and ocular complications or visual loss. On 
the other hand, elevated flare (≥20photons/
msec) has been found to be a strong predictor 
of complications and visual loss.30 Laser flare 
photometry is therefore an essential tool in the 
follow-up of children with chronic anterior 
uveitis.
Idiopathic Intermediate Uveitis (Pars Planitis)
According to the anatomic classification of 
uveitis by the Standardization of Uveitis 
Nomenclature (SUN) Working Group, the 
term “intermediate uveitis” defines a subset of 
uveitis where the vitreous is the primary site of 
inflammation. Pars planitis is a diagnostic term 
that defines a subset of idiopathic intermediate 
uveitis where there is snowbank or snowball 
formation.31 This disease typically affects 
children and adolescents. The association of 
intermediate uveitis with a systemic disease 
is very rare in children. Associations between 
idiopathic intermediate uveitis and HLA-DR2 
and HLA-DR15 have been reported suggesting 
an immunogenetic predisposition.32,33 A strong 
association of multiple sclerosis with the same 
HLA antigens suggests a common genetic 
background.
Young children with pars planitis are 
usually asymptomatic and diagnosed during 
a routine ophthalmologic examination. Some 
children are diagnosed only after significant 
visual impairment or the development 
of complications that cause leukocoria or 
strabismus. Most children have bilateral 
symmetrical involvement.
Typical clinical findings include mild to 
moderate anterior segment inflammation, 
diffuse vitreous cells and haze, and snowballs 
and snowbanks located inferiorly (Fig. 4). Band 
keratopathy, peripheral corneal endotheliopathy 
(Fig. 5), and posterior synechiae may be seen 
in childhood pars planitis but are very rare in 
adults. Optic disc edema and cystoid macular 
edema are the most frequent complications.34
Neovascularization of the optic disc or 
associated with snowbanks may cause vitreous 
hemorrhage and is more common in children 
than adults with pars planitis. Inferior peripheral 
Figure 3. Slit lamp photography using diffuse 
illumination at high magnification shows seclusion of 
the pupil in a child with JIA-associated anterior uveitis.
Figure 4. Fundus photograph shows inferiorly located 
snow ball opacities and vitreous veils in a child with pars 
planitis.Pediatric Uveitis; Tugal-Tutkun
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retinoschisis is another complication that 
develops almost exclusively in children (Fig. 6).35 
Dense vitreous condensation may cause 
leukocoria, sometimes mistaken for cataracts 
(Fig. 7). However, posterior subcapsular 
cataract may also develop early in the course 
of the disease.36 Although vitreous haze and 
cataracts may cause amblyopia in a young child 
with pars planitis, cystoid macular edema is 
the leading cause of visual morbidity.34,35 In a 
long-term follow-up study, visual prognosis 
was reported to be good despite the high rate 
of ocular complications in children with pars 
planitis. However, a recent study has shown 
that children with onset of disease at 7 years 
of age or younger were at higher risk of 
complications such as cataract, glaucoma, and 
vitreous hemorrhage, and had worse visual 
prognosis than older children.37 Periocular 
corticosteroid injections and short-term oral 
steroids are used in patients who have sight-
threatening intraocular inflammation, especially 
cystoid macular edema. Repeated corticosteroid 
injections may induce ocular hypertension.34 
Methotrexate and cyclosporine may be used 
as steroid-sparing agents. Children with severe 
intermediate uveitis of the pars planitis type 
may even require treatment with biologic 
agents. In a retrospective analysis of 20 children 
with refractory uveitis treated with infliximab, 
8 had idiopathic pars planitis.38 Infliximab 
infusions could be discontinued in 2 of them 
after 7 and 12 infusions because remission 
could be sustained with only antimetabolites. 
Intraocular inflammation was controlled in all 
of the remaining 6 pars planitis patients with 
repeated infliximab infusions and a concomitant 
antimetabolite agent without any need for oral 
corticosteroids.38
Behçet Uveitis
The peak age of onset for Behçet disease is in 
the third or fourth decade of life. Although 
the onset of recurrent oral ulcers in childhood 
is not uncommon, patients typically fulfill the 
diagnostic criteria after the age of 16 years. 
There are no internationally accepted diagnostic 
Figure 5. Slit lamp photograph shows peripheral corneal 
edema due to peripheral corneal endotheliopathy 
localized to the inferior-temporal cornea of the left eye in 
a child with pars planitis.
Figure 6. Fundus photograph shows inferior retinoschisis 
in a child with pars planitis.
Figure 7. Slit lamp photograph shows dense vitreous 
condensation and opacities adherent to the posterior lens 
capsule in a child with pars planitis. Also note irregular 
pupil dilation due to posterior synechiae in this eye.Pediatric Uveitis; Tugal-Tutkun
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criteria for childhood-onset Behçet disease. 
In a recent international registry of patients 
suspected of pediatric Behçet disease, the 
presenting symptom was isolated recurrent 
oral ulcers in 83%, and the diagnosis was 
confirmed by an expert committee in 62% of 
registered cases. Uveitis was less common 
(34%) in this group than in adults.39 From an 
ophthalmological point of view, pediatric Behçet 
uveitis is defined as onset of uveitis at 16 years 
of age or younger irrespective of the age for 
fulfilling the diagnostic criteria. There may be 
variations in the prevalence of pediatric Behçet 
disease in different ethnic groups or geographic 
regions. In an international retrospective survey, 
more than half of the children with Behçet 
uveitis were from Middle Eastern countries as 
compared to only 2.4% from East/South Asia, 
in contrast 19.2% of adults belonged to the latter 
ethnic group.40 However, several sources of 
bias may have confounded the results of this 
survey. Even in Turkey, one of the countries 
with the highest prevalence of Behçet disease, 
only 3.5% of patients with Behçet uveitis are in 
the pediatric age group [unpublished data from 
the Turkish Registry of Uveitis (BUST study)].
Mean age at onset of pediatric Behçet 
uveitis is in late childhood (10-15 years).41-44 
There is a male predominance in the pediatric 
age group, similar to adult-onset Behçet 
uveitis.39-44 A positive family history has been 
reported in 20-47% of pediatric cases from 
endemic areas, implying the role of genetic 
factors in the early onset of the disease.39,41,42,45 
Otherwise, the clinical picture in children is not 
different from adults. The majority of patients 
have bilateral involvement and recurrent 
panuveitis with retinal vasculitis.40,41,43,44 
Cataract, intraocular pressure elevation, macular 
edema or maculopathy, and optic atrophy 
are the most common complications.41,43-45 
While visual prognosis has been reported 
to be better than adults in some series40,43, 
individual variability of the disease course, 
response to treatment and visual outcome 
has been reported by others.41,44,45 Children 
with posterior segment involvement require 
immunosuppressive therapy. Biologic agents 
are used in patients refractory to conventional 
immunosuppressive therapy. In a series of 
seven patients with corticosteroid dependent 
Behçet uveitis, treatment with interferon-
alpha showed a corticosteroid-sparing effect 
with induction of remission in five patients; 
remission was sustained in four of them even 
after discontinuation of treatment in three.46
Tubulointerstitial Nephritis and Uveitis 
(TINU) Syndrome
TINU is an uncommon syndrome accounting for 
1.7% of all cases of adult uveitis.47 However, it 
is a more common cause of uveitis in children 
and adolescents with a median age of onset of 
15 years.48 Diagnosis is based on the concurrence 
of acute tubulointerstitial nephritis (TIN) and 
bilateral acute anterior uveitis.49 Uveitis may 
not occur simultaneously, but may precede 
or more commonly follow renal disease.48 For 
a definite diagnosis, a renal biopsy may be 
performed. A clinical diagnosis of TIN is often 
based on the presence of systemic symptoms, 
including fever, weight loss, abdominal and 
flank pain, and arthralgia associated with renal 
dysfunction evidenced by increasing urea and 
creatinine levels, proteinuria, microhematuria, 
and glycosuria.49 An elevated urinary beta-2-
microglobulin level has been reported as a very 
helpful laboratory marker.48-50
The typical presentation of TINU is an 
acute bilateral anterior uveitis, often with pain 
and photophobia. While topical corticosteroids 
may be sufficient in such cases, systemic 
corticosteroids and even immunosuppressive 
therapy may be required for renal disease or 
for patients who develop chronic recurrent 
anterior uveitis leading to ocular complications. 
Atypical cases with posterior or panuveitis 
may also require more aggressive treatment. 
Visual prognosis is generally good.48-50 In a 
recent retrospective study of 26 Finnish children 
with TIN, bilateral anterior uveitis was found 
in 12 subjects (46%).51 No correlation was 
found between renal disease and uveitis which 
preceded TIN by one month in one patient 
and followed TIN by 2 weeks to 15 months in 
others. Four of the 12 patients (33%) developed 
chronic uveitis and remission was achieved Pediatric Uveitis; Tugal-Tutkun
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only after anti-tumor necrosis factor (TNF) 
treatment in one of them.51
Sarcoidosis
Childhood sarcoidosis is a rare multisystemic 
granulomatous inflammatory disorder. While 
older children may present with pulmonary 
involvement, young children typically present 
with a triad of arthritis, skin lesions and uveitis. 
Serum angiotensin-converting enzyme levels 
may be misleading because children tend to have 
higher levels than adults.52 Although a biopsy 
specimen showing non-caseating granulomatous 
inflammation is required for a definite diagnosis, 
the clinical diagnosis of ocular sarcoidosis can 
be made, at least in older children, based on 
typical signs of ocular disease and presence of 
laboratory abnormalities.53
Anterior uveitis is the most common type 
of involvement in children with sarcoidosis. 
Granulomatous KPs, iris nodules, and peripheral 
and broad-based posterior synechiae are 
typical findings. Chronic uncontrolled anterior 
uveitis may lead to complications such as band 
keratopathy cataracts, and glaucoma. Sometimes 
it is difficult to differentiate this clinical picture 
from JIA-associated uveitis. Inflammation of 
the posterior segment in the form of retinal 
vasculitis or multifocal choroiditis can be seen in 
sarcoidosis; however, intraocular inflammation 
is typically confined to the anterior segment 
in JIA-associated uveitis although posterior 
segment findings may develop as a complication 
of uncontrolled anterior uveitis.
Familial juvenile systemic granulomatosis, 
also known as Blau syndrome, has an 
autosomal dominant mode of inheritance and 
is characterized by granulomatous polyarthritis, 
skin rash and acute granulomatous anterior 
uveitis resembling sarcoidosis in young 
children.54,55 Since Blau syndrome is clinically 
indistinguishable from early-onset sarcoidosis, 
family history is an essential component in the 
assessment of children who present with these 
manifestations. The genetic mutation for both 
has been shown to involve the CARD15/NOD2 
gene on chromosome 16q12, inherited in an 
autosomal dominant pattern in Blau syndrome 
but arising de novo in infantile sarcoidosis.56
TREATMENT OF NONINFECTIOUS 
UVEITIS IN CHILDREN
Exclusion of an infectious cause of uveitis and 
masquerade syndromes is of utmost importance 
before the administration of nonspecific 
anti-inflammatory and immunomodulatory 
treatment. Corticosteroids remain first-line 
treatment for noninfectious uveitis in children. 
Topical corticosteroids are initially used for 
treatment of anterior segment inflammation. 
Periocular or subtenon corticosteroid injections 
may be used for treatment of intermediate or 
posterior uveitis, especially in unilateral cases 
or for the treatment cystoid macular edema. 
Prolonged use of topical corticosteroids and 
repeated periocular injections are associated 
with a higher risk of ocular complications in 
children.57-59 Intraocular pressure elevation 
and steroid-induced glaucoma occur more 
rapidly and may be refractory to treatment in 
children. It is difficult to detect and monitor 
intraocular pressure elevation especially 
in young, noncompliant children. Multiple 
periocular injections may also result in systemic 
corticosteroid complications.60 Intravitreal 
injections may prevent systemic side effects, but 
potential risks and rate of ocular complications 
are higher.
Systemic corticosteroids are used only for 
short-term treatment in children because of 
significant systemic side effects associated with 
their prolonged use, including cushingoid status, 
growth retardation, weight gain, hypertension, 
osteoporosis, gastrointestinal disturbance, 
psychosis and electrolyte imbalance. The usual 
induction dose of oral prednisolone is 1-2mg/
kg. Intravenous pulse methyl-prednisolone 
30mg/kg may be preferred when more rapid 
and potent action is needed. Patients who do not 
adequately respond to high dose corticosteroids 
will need immunosuppressive treatment. For 
patients who become corticosteroid-dependent, 
a corticosteroid-sparing immunosuppressive 
agent is administered. In patients who present 
with serious ocular complications and risk 
factors for development of new complications, Pediatric Uveitis; Tugal-Tutkun
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immunosuppressive agent(s) combined with 
corticosteroids may be started at initial visit.
Methotrexate is the most widely used 
first-line immunomodulatory agent in children 
with uveitis because of its long-term safety 
profile in this age group. In a recently reported 
series of JIA-associated uveitis, improvement 
of inflammation was achieved in 82% of 
patients treated with methotrexate for at least 3 
months.61 A longer duration of inactivity during 
methotrexate therapy was found to be associated 
with a lower risk of relapse after discontinuation 
of this agent.61 Second-line immunosuppressive 
agents include azathioprine, cyclosporine 
and mycophenolate. Alkylating agents, such 
as cyclophosphamide and chlorambucil, are 
generally avoided in children because of serious 
potential side effects. These agents have been 
used in children with emergency situations 
such as systemic lupus erythematosus or other 
life-threatening vasculitides.
Anti-TNF agents are used in patients who fail 
to respond to conventional immunosuppressive 
therapy and are at a high risk of visual loss. 
Both infliximab and adalimumab have been 
successfully used for treatment of resistant 
pediatric uveitis.38,62-69 The convenience of 
subcutaneous administration, stable serum 
concentrations, and more favorable safety profile 
are advantages of adalimumab over intravenous 
infliximab infusions for treatment of uveitis in 
children. However, the fast-onset and potent 
anti-inflammatory effect of infliximab may be 
desirable for immediate control of intraocular 
inflammation, for example in children who 
need emergency ocular surgery.38Another anti-
TNF agent, etanercept, which is effective in 
the treatment of rheumatic disease in children, 
is not recommended for treatment of uveitis. 
Smith et al reported no significant difference 
between placebo and etanercept in a randomized 
controlled trial.70 Furthermore, several cases 
of new-onset uveitis have been reported in 
patients receiving etanercept for rheumatologic 
disorders.71,72 In patients refractory to anti-TNF 
agents, alternative biologic agents may be 
tried such as anakinra, daclizumab, abatacept, 
rituximab, and tocilizumab.57,73-75 Experience 
with these agents is currently limited to small 
series of selected patients. Furthermore, potential 
serious adverse effects such as an increased risk 
of opportunistic infections and malignancies 
should be carefully weighed against benefits 
of biologic therapy in this particular age group 
who have long life expectancy.
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